Lyra Therapeutics (LYRA) Shares Outstanding (Diluted Average) (2021 - 2025)
Quarterly Shares Outstanding (Diluted Average) rose 19.29% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 19.29% year-over-year, with the annual reading at $1.6 million for FY2025, 19.29% up from the prior year.
Lyra Therapeutics' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $1.6 million for Q4 2025.
- Shares Outstanding (Diluted Average) came in at $1.6 million for Q4 2025, down from $1.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $65.8 million in Q1 2025 to a low of $1.3 million in Q2 2024.
- The 5-year median for Shares Outstanding (Diluted Average) is $13.0 million (2021), against an average of $23.1 million.
- Year-over-year, Shares Outstanding (Diluted Average) soared 183.14% in 2023 and then crashed 97.39% in 2024.
- Lyra Therapeutics' Shares Outstanding (Diluted Average) stood at $13.0 million in 2021, then skyrocketed by 132.83% to $30.2 million in 2022, then skyrocketed by 64.72% to $49.8 million in 2023, then plummeted by 97.39% to $1.3 million in 2024, then rose by 19.29% to $1.6 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Shares Outstanding (Diluted Average) are $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 107.70 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Lyra Therapeutics | - | - | - | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 65.76 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 64.01 Mn |
| Dec 31, 2023 | 49.80 Mn |
| Sep 30, 2023 | 45.89 Mn |
| Jun 30, 2023 | 43.68 Mn |
| Mar 31, 2023 | 36.83 Mn |
| Dec 31, 2022 | 30.24 Mn |
| Sep 30, 2022 | 28.01 Mn |
| Jun 30, 2022 | 23.54 Mn |
| Mar 31, 2022 | 13.01 Mn |
| Dec 31, 2021 | 12.99 Mn |
| Sep 30, 2021 | 12.98 Mn |
| Jun 30, 2021 | 12.97 Mn |
| Mar 31, 2021 | 12.95 Mn |